Stocktoria
Viridian Therapeutics, Inc.DE VRDN
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2014-06-18
Viridian Therapeutics, Inc.DE financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $70.8M | $302,000 | $314,000 | $1.8M | $3.0M |
| SG&A expense | $95.3M | $61.1M | $95.0M | — | — |
| Operating income | -$363.4M | -$299.0M | -$254.4M | -$134.3M | -$79.7M |
| Interest expense | — | — | — | $500,000 | — |
| Income tax | $0 | — | — | — | — |
| Net income | -$342.6M | -$269.9M | -$237.7M | -$129.9M | -$79.4M |
| EPS (diluted) | — | — | $-5.31 | $-4.05 | $-6.66 |
| Operating cash flow | -$276.4M | -$232.3M | -$184.2M | -$93.8M | -$54.6M |
| Free cash flow | -$276.9M | -$232.8M | -$185.1M | -$94.6M | -$54.9M |
| Total assets | $899.4M | $742.4M | $490.4M | $435.1M | $203.7M |
| Total liabilities | $177.3M | $70.8M | $48.4M | $40.0M | $16.0M |
| Shareholders' equity | $722.2M | $671.6M | $442.0M | $395.1M | $187.7M |
Source: SEC EDGAR filings · CIK 0001590750 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.